ARMP AMEX
Credit Risk of going bust: higher than 95% of companies Debt: 71.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $1.48 (down 57%), Armata Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $314.0M against a stock market value of $128.3M.
Distance to default 0.51 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $267.1M (short-term plus half of long-term), stock volatility 113.6%; Altman Z'' -49.45. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Los Angeles, CA 90066
US
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Birx Deborah | F-InKind | 14,041 | $4.26 | 2026-07-10 |
| Gilmer Daniel B. | A-Award | 51,280 | $12.92 | 2026-04-24 |
| Gilmer Daniel B. | 0 | — | 2026-04-24 | |
| Kyme Pierre | F-InKind | 1,030 | $10.54 | 2026-03-14 |
| Birx Deborah | F-InKind | 4,919 | $10.54 | 2026-03-14 |